SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 30, 2004
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
|(State or Other Jurisdiction
|3200 Walnut Street, Boulder, Colorado||80301|
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant's telephone number, including area code: (303) 381-6600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On November 30, 2004, Array BioPharma Inc. issued a press release announcing that it plans to file a prospectus supplement with the Securities and Exchange Commission for the sale of 6,000,000 shares of its common stock in an underwritten offering pursuant to an existing shelf registration statement. A copy of the press release is attached hereto as Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARRAY BIOPHARMA INC.
Date: November 30, 2004
/s/ ROBERT E. CONWAY
Robert E. Conway
Chief Executive Officer